Proteomic analysis of exfoliation deposits

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 4, 2007, Pages 1447-1457

  Ovodenko, Boris ^a   Rostagno, Agueda ^b   Neubert, Thomas A ^b   Shetty, Vivekananda ^b   Thomas, Stefani ^c   Yang, Austin ^c   Liebmann, Jeffrey ^a,b   Ghiso, Jorge ^b   Ritch, Robert ^a,d  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID P COMPONENT; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C1Q; CYANOGEN BROMIDE; DESMOCOLLIN; ELASTASE; FIBRILLIN 1; FIBRONECTIN; FORMIC ACID; LAMININ; METALLOPROTEINASE; SYNDECAN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRYPSIN; VERSICAN; VITRONECTIN; CELL ADHESION MOLECULE; EYE PROTEIN; MEMBRANE PROTEIN; PROTEOME; SCLEROPROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXFOLIATION SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; LENS CAPSULE; LIQUID CHROMATOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEOMICS; SILVER STAINING; TANDEM MASS SPECTROMETRY; CATARACT EXTRACTION; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CATARACT EXTRACTION; CELL ADHESION MOLECULES; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXFOLIATION SYNDROME; EXTRACELLULAR MATRIX PROTEINS; EYE PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LENS CAPSULE, CRYSTALLINE; MEMBRANE PROTEINS; MIDDLE AGED; PROTEOME; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 34248389332     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0411     Document Type: Article

References (91)

1. Ritch R. Exfoliation syndrome: the most common identifiable cause of open-angle glaucoma. J Glaucoma. 1994;3:176-178.
2. Ritch R. Exfoliation syndrome. Curr Opin Ophthalmol. 2001;12: 124-130.
3. Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265-315.
4. Naumann GOH, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology. 1998;105:951-968.
5. Streeten BW, Gibson G, Dark AJ. Pseudoexfoliative material contains an elastic microfibrillar-associated glycoprotein. Trans Am Ophthalmol Soc. 1986;84:304-320.
6. Schlötzer-Schrehardt U, von der Mark K, Sakai LY, Nauman GO. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci. 1997;38: 970-984.
7. Schlötzer-Schrehardt U, Dorfler S, Naumann GO. Immunohistochemical localization of basement membrane components in pseudoexfoliation material of the lens capsule. Curr Eye Res. 1992;11:343-355.
8. Li ZY, Streeten BW, Wallace RN. Association of elastin with pseudoexfoliative material: an immunoelectron microscopic study. Curr Eye Res. 1988;12:1163-1172.
9. Li ZY, Streeten BW, Yohai N. Amyloid P protein in pseudoexfoliative fibrillopathy. Curr Eye Res. 1989;8:217-227.
10. Schlötzer-Schrehardt U, Zenkel M, Küchle M, Sakai LY, Nauman GO. The role of transforming growth factor-β1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res. 2001;73:765-780.
11. Ringvold A, Husby G, Pettersen S. Electrophoretic study of proteins associated with pseudoexfoliation syndrome. Acta Ophthalmol (Copenh). 1989;67:724-726.
12. Gharahdaghi F, Weinberg CR, Meagher DA, Imai BS, Mische SM. Mass spectrometric identification of proteins from silver-stained polyacrylamide gel: a method for the removal of silver ions to enhance sensitivity. Electrophoresis. 1999;20:601-605.
13. Jordan BA, Fernholz BD, Boussac M, et al. Identification and verification of novel rodent postsynaptic density proteins. Mol Cell Proteomics. 2004;3:857-871.
14. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis. 1999;20:3551-3567.
15. Thomas SN, Soreghan B, Nistor N, Sarsoza F, Head E, Yang AJ. Reduced neuronal expression of synaptic transmission modulator HNK-1/neural adhesion molecule as a potential consequence of amyloid beta-mediated oxidative stress: a proteomic approach. J Neurochem. 2005;92:705-717.
16. Kaplan B, Hrncic R, Murphy CL, Gallo G, Weiss DT, Solomon A. Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue. Methods Enzymol. 1999;309:67-81.
17. Gross E, Witko B. Nonenzymatic cleavage of peptide bonds: the methionine residues in bovine pancreatic ribonuclease. J Biol Chem. 1962;237:1856-1860.
18. Gross E. The cyanogen bromide reaction. Methods Enzymol. 1967;11:238-255.
19. Piszkiewicz D, Landon M, Smith EL. Anomalous cleavage of aspartyl-proline peptide bonds during amino acid sequence determinations. Biochem Biophys Res Commun. 1970;40:1173-1178.
20. Amari F, Umihira J, Nohara M, et al. Electron microscopic immunohistochemistry of ocular and extraocular pseudoexfoliative material. Exp Eye Res. 1997;65:51-56.
21. Ritch R, Schlötzer-Schrehardt U. Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Acta Ophthalmol Scand. 2001;79:213-217.
22. Ragunath M, Cankay R, Kubitscheck U, et al. Transglutaminase activity in the eye: crosslinking in epithelia and connective tissue structures. Invest Ophthalmol Vis Sci. 1999;40:2780-2787.
23. Tomidokoro Y, Lashley T, Rostagno A, et al. Familial Danish dementia: co-existence of ADan and Aβ amyloid subunits in the absence of compact plaques. J Biol Chem. 2005;280:36883-36894.
24. Wetzel R. Amyloid, Prions, and Other Protein Aggregates. New York: Elsevier Inc.; 1999.
25. Zenkel M, Poschl E, von der Mark K, et al. Differential gene expression in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci. 2005;46:3742-3752.
26. Schlötzer-Schrehardt U, Nauman GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol. 2006;141:921-937.
27. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. EMBO J. 2003;4:1127-1131.
28. Timpl R, Sasaki T, Kostka G, Chu M-L. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol. 2003;4:479-489.
29. Garrod DR, Merritt AJ, Nie Z. Desmosomal adhesion: structural basis, molecular mechanism and regulation. Mol Membr Biol. 2002;19:81-94.
30. Messent AJ, Blissett MJ, Smith GL, et al. Expression of a single pair of desmosomal glycoproteins renders the corneal epithelium unique amongst stratified epithelia. Invest Ophthalmol Vis Sci. 2000;41:8-15.
31. Morrison JC, Green WR. Light microscopy of the exfoliation syndrome. Acta Ophthalmol Suppl. 1988;184:5-27.
32. Winkler J, HL, Wirbelauer C, Reinhardt DP, Laqua H. Immunohistochemical and charge-specific localization of anionic constituents in pseudoexfoliation deposits on the central anterior lens capsule from individuals with pseudoexfoliation syndrome. Graefes Arch Clin Exp Ophthalmol. 2001;239:952-960.
33. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617-623.
34. Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, Sakai LY. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem. 2002;277: 4565-4572.
35. Olin AI, Morgelin M, Sasaki T, Timpl R, Heinegard D, Aspberg A. The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem. 2001; 276:1253-1261.
36. Zhao X, Russell P. Versican splice variants in human trabecular meshwork and ciliary muscle. Mol Vision. 2005;11:603-608.
37. Bandtlow CE, Zimmermann D. Proteoglycans in the developing brain: New conceptual insights for old proteins. Physiol Rev. 2000;80:1267-1290.
38. Filla MS, David G, Weinreb RN, Kaufman PL, Peters DM. Distribution of syndecans 1-4 within the anterior segment of the human eye: expression of a variant syndecan-3 and matrix-associated syndecan-2. Exp Eye Res. 2004;79:61-74.
39. Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AGP, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/ glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
40. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005;386:15-27.
41. Colige A, Li SW, Sieron AL, Nusgens BV, Prockop DJ, Lapiere CM. cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc Natl Acad Sci USA. 1997;94:2374-2379.
42. Collins-Racie LA, Flannery CR, Zeng W, et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol. 2004;23:219-230.
43. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family proteins. Science. 1999;284:1664-1666.
44. Yang P, Baker A, Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog Neurobiol. 2006;79:73-94.
45. Dunn JR, Reed JE, du Plessis DG, et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumors. Br J Cancer. 2006;94:1186-1193.
46. Visse R, Nagase H. Matrix metalloproteases and tissue inhibitors of metalloproteases. Circ Res. 2003;92:827-839.
47. Ho SL, Dogar GF, Wang J, et al. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br J Ophthalmol. 2005;89:169-173.
48. Barbazetto IA, Hayashi M, Klais CM, Yannuzzi LA, Allikmets R. A novel TIMP3 mutation associated with Sorsby fundus dystrophy. Arch Ophthalmol. 2005;123:542-543.
49. Tenner AJ. Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol Aging. 2001;22:849-861.
50. Morgan BP. The complement system: an overview. In: Morgan BP, ed. Complement Methods and Protocols. Clifton, NJ: Humana Press; 2000:1-13.
51. Emmerling MR, Watson MD, Raby CA, Spiegel K. The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta. 2000;1502:158-171.
52. McDonald JF, Nelsestuen GL. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry. 1997;36:7464-7473.
53. Milis L, Morris C, Sheehan MC, Charlesworth JA, Pussell BA. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol. 1993;92:114-119.
54. Damji KF, Bains HS, Stefansson E, et al. Is pseudoexfoliation syndrome inherited? - a review of genetic and non-genetic factors and a new observation. Ophthalmic Genet. 1998;19:175-185.
55. Morgan BP. Regulation of the complement membrane attack pathway. Crit Rev Immunol. 1999;19:173-198.
56. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's Disease. Neurobiol Aging. 2000;21:383-421.
57. Rostagno A, Tomidokoro Y, Lashley T, et al. Chromosome 13 dementias. Cell Mol Life Sci. 2005;62:1814-1825.
58. Lashley T, Holton J, Verbeek MM, et al. Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. J Neuropathol Exp Neurol. 2006;32:492-504.
59. Rostagno A, Revesz T, Lashley T, et al. Complement activation in Chromosome 13 dementias: similarities with Alzheimer's Disease. J Biol Chem. 2003;277:49782-49790.
60. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res. 2001;73:887-896.
61. Dotsenko V, Neshkova E, Namazova I, Vavilova L, Yarovaya G. Hageman factor and kallikrein in pathogenesis of senile cataracts and the pseudoexfoliation syndrome. Immunopharmacology. 1996;32:141-145.
62. Zenkel M, Kruse FE, Jünemann A, Naumann GO, Schlötzer- Schrehardt U. Clusterin deficiency in eyes with pseudoexfoliation syndrome may be implicated in the aggregation and deposition of pseudoexfoliative material. Invest Ophthalmol Vis Sci. 2006;47: 1982-1990.
63. Calero M, Rostagno A, Frangione B, Ghiso J. Clusterin and Alzheimer's disease. Subcell Biochem. 2005;38:273-298.
64. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech. 2000;50:305-315.
65. Jin G, Howe PH. Regulation of clusterin gene expression by trans3 forming growth factor beta. J Biol Chem. 1997;272:26620-26626.
66. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem. 2003;278:11590-11600.
67. Collard M, Griswold M. Biosynthesis and molecular cloning of sulfated glycoprotein 2 secreted by rat Sertoli cells. Biochemistry. 1987;26:3297-3303.
68. deSilva H, Harmony J, Stuart W, Gil C, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry. 1990;29:5380-5389.
69. Sylvester S, Morales C, Oko R, Griswold M. Localization of sulfated glycoprotein (clusterin) on spermatozoa and in the reproductive tract of the male rat. Biol Reprod. 1991;45:195-207.
70. Aronow BJ, Lund SD, Brown TL, Harmony J, Wite DP. Apolipoprotein J expression at fluid-tissue interphases: potential role in barrier cytoprotection. Proc Natl Acad Sci USA. 1993;90:725-729.
71. Nishida K, Kawasaki S, Adachi W, Kinoshita S. Apolipoprotein J expression in human ocular surface epithelium. Invest Ophthalmol Vis Sci. 1996;37:2285-2292.
72. Nishida K, Adachi W, Shimizu-Matsumoto A, et al. A gene expression profile of human corneal epithelium and the isolation of human keratin 12 cDNA. Invest Ophthalmol Vis Sci. 1996;37: 1800-1809.
73. Dota A, Nishida K, Quantock AJ, Kinoshita S. Clusterin in human corneal endothelium and aqueous humor. Exp Eye Res. 1999;69: 705-708.
74. Jomary C, Neal MJ, Jones SE. Comparison of clusterin gene expression in normal and dystrophic human retinas. Mol Brain Res. 1993;20:279-284.
75. Reeder DJ, Stuart WD, Witte DP, Brown TL, Harmony JAK. Local synthesis of apolipoprotein J in the eye. Exp Eye Res. 1995;60: 495-504.
76. Jones SE, Meerabux JM, Yeats DA, Neal MJ. Analysis of differentially expressed genes in retinitis pigmentosa retinas: altered expression of clusterin mRNA. FEBS Lett. 1992;300:279-282.
77. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem. 1991;266:11030-11036.
78. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem. 1999;274:6875-6881.
79. Michel D, Chatelain G, North S, Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J. 1997;328:45-50.
80. Nishida K, Quantock AJ, Dota A, Choi-Miura NH, Kinoshita S. Apolipoproteins J and E co-localize with amyloid in gelatinous drop-like and lattice type I corneal dystrophies. Br J Ophthalmol. 1999;83:1178-1182.
81. Reddy KB, Jin G, Karode MC, Harmony JAK, Howe PH. Transforming growth factor b (TGFβ)-induced nuclear localization of apolipoprotein J (clusterin) in epithelial cells. Biochemistry. 1996;35: 6157-6163.
82. Wegrowski Y, Perreau C, Martiny L, Haye B, Maquart FX, Bellon G. Transforming growth factor beta-1 up-regulates clusterin synthesis in thyroid epithelial cells. Exp Cell Res. 1999;247:475-485.
83. Frippiat C, Chen QM, Zdanov S, Magalhaes JP, Remade J, Toussaint O. Subcytotoxic H2O2 stress triggers a release of transforming growth factor-1, which induces biomarkers of cellular senescence of human diploid fibroblasts. J Biol Chem. 2001;276:2531-2537.
84. Morgan TE, Laping NJ, Rozovsky I, et al. Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions. J Neuroimmunol. 1995;58:101-110.
85. Thomas-Salgar S, Millis AJ. Clusterin expression in differentiating smooth muscle cells. J Biol Chem. 1994;269:17879-17885.
86. Jin G, Howe PH. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fps. Eur J Biochem. 1999;263:534-542.
87. Helbig H, Schlötzer-Schrehardt U, Noske W, Kellner U, Foerster MH, Naumann GO. Anterior chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger J Ophthalmol. 1994;3: 148-153.
88. Zoric L, Miric D, Milenkovic S, Jovanovic P, Trajkovic G. Pseudoexfoliation syndrome and its antioxidative protection deficiency as risk factors for age-related cataract. Eur J Ophthalmol. 2006;16: 268-273.
89. Ucakhan OO, Karel F, Kanpolat A, Devrim E, Durak I. Superoxide dismutase activity in the lens capsule of patients with pseudoexfoliation syndrome and cataract. J Cataract Refract Surg. 2006;32: 618-622.
90. Gartaganis SP, Georgakopoulos CD, Patsoukis NE, Gotsis SS, Gartaganis VS, Georgiou CD. Glutathione and lipid peroxide changes in pseudoexfoliation syndrome. Curr Eye Res. 2005;30:647-651.
91. Ghiso J, Frangione B. Amyloidosis and Alzheimer's disease. Adv Drug Delivery Rev. 2002;54:1539-1551.